Fl118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models

American Journal of Translational Research

Volumn 7, Issue 10, 2015, Pages 1765-1781

  Ling, Xiang ^a,b   Liu, Xiaojun ^a   Zhong, Kai ^b   Smith, Nicholas ^b   Prey, Joshua ^a   Li, Fengzhi ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Canget BioTekpharma LLC   (United States)

Author keywords

Animal models of human tumor Xenografts; Antitumor activity; FL118; Irinotecan; Topotecan; Treatment resistance

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC AGENT FL118; BREAST CANCER RESISTANCE PROTEIN; FIRTECAN; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN MCL 1; SILDENAFIL; SURVIVIN; TOPOTECAN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CELL GROWTH; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IC50; MAXIMUM PLASMA CONCENTRATION; MOUSE; MTT ASSAY; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR GROWTH; WESTERN BLOTTING;

EID: 84947803678     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT and Sim GA. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminate. J Am Chem Soc 1966; 88: 3888-3890.
2. Liew ST and Yang LX. Design, synthesis and development of novel camptothecin drugs. Curr Pharm Des 2008; 14: 1078-1097.
3. Li QY, Zu YG, Shi RZ and Yao LP. Review camptothecin: current perspectives. Curr Med Chem 2006; 13: 2021-2039.
4. Chen MC, Lee NH, Ho TJ, Hsu HH, Kuo CH, Kuo WW, Lin YM, Tsai FJ, Tsai CH and Huang CY. Resistance to irinotecan (CPT-11) activates epidermal growth factor receptor/nuclear factor kappa B and increases cellular metastasis and autophagy in LoVo colon cancer cells. Cancer Lett 2014; 349: 51-60.
5. Bessho Y, Oguri T, Achiwa H, Muramatsu H, Maeda H, Niimi T, Sato S and Ueda R. Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer. Cancer Sci 2006; 97: 192-198.
6. Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, Johnston B, Scheper RJ, Stewart CF and Schuetz JD. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 2004; 24: 7612-7621.
7. Cruz-Munoz W, Di Desidero T, Man S, Xu P, Jaramillo ML, Hashimoto K, Collins C, Banville M, O’Connor-McCourt MD and Kerbel RS. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer. Angiogenesis 2014; 17: 661-673.
8. Nemunaitis J, Cox J, Meyer W, Courtney A and Mues G. Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU). Am J Clin Oncol 1997; 20: 527-529.
9. Saraiya B, Gounder M, Dutta J, Saleem A, Collazo C, Zimmerman L, Nazar A, Gharibo M, Schaar D, Lin Y, Shih W, Aisner J, Strair RK and Rubin EH. Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia. Anticancer Drugs 2008; 19: 411-420.
10. Ling X, Cao S, Cheng Q, Keefe JT, Rustum YM and Li F. A Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner, Shows Superior Antitumor Activity. PLoS One 2012; 7: e45571.
11. Liu LF, Desai SD, Li TK, Mao Y, Sun M and Sim SP. Mechanism of action of camptothecin. Ann N Y Acad Sci 2000; 922: 1-10.
12. Kang MR, Muller MT and Chung IK. Telomeric DNA damage by topoisomerase I. A possible mechanism for cell killing by camptothecin. J Biol Chem 2004; 279: 12535-12541.
13. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB Jr and Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A 2002; 99: 15387-15392.
14. Ling X and Li F. An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI). Am J Transl Res 2013; 5: 139-154.
15. Zhao J, Ling X, Cao S, Liu X, Wan S, Jiang T and Li F. Antitumor activity of FL118, a survivin, Mcl-1, XIAP, cIAP2 selective inhibitor, is highly dependent on its primary structure and steric configuration. Mol Pharm 2014; 11: 457-467.
16. Li F. Anticancer drug FL118 is more than a survivin inhibitor: Where is the Achilles’ heel of cancer? Am J Cancer Res 2014; 4: 304-311.
17. Nakatomi K, Yoshikawa M, Oka M, Ikegami Y, Hayasaka S, Sano K, Shiozawa K, Kawabata S, Soda H, Ishikawa T, Tanabe S and Kohno S. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun 2001; 288: 827-832.
18. Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, Soda H, Fukuda M, Ikegami Y, Sugahara K, Yamada Y, Kamihira S, Doyle LA, Ross DD and Kohno S. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 2001; 280: 1216-1223.
19. Li H, Jin HE, Kim W, Han YH, Kim DD, Chung SJ and Shim CK. Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. Pharm Res 2008; 25: 2601-2612.
20. de Vries NA, Zhao J, Kroon E, Buckle T, Beijnen JH and van Tellingen O. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res 2007; 13: 6440-6449.
21. Jia P, Wu S, Li F, Xu Q, Wu M, Chen G, Liao G, Wang S, Zhou J, Lu Y and Ma D. Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells. Int J Gynecol Cancer 2005; 15: 1042-1048.
22. Westover D, Ling X, Lam H, Welch J, Jin C, Gongora C, Del Rio M, Wani M and Li F. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance. Mol Cancer 2015; 14: 92.
23. Ling X, Xu C, Fan C, Zhong K, Li F and Wang X. FL118 Induces p53-Dependent Senescence in Colorectal Cancer Cells by Promoting Degradation of MdmX. Cancer Res 2014; 74: 7487-7497.
24. Li F, Ling X, Cao S, inventors; Roswell Park Cancer Institute, assignee. Novel Formulations of Water-Insoluble Chemical Compounds and Methods of Using a Formulation of Compound FL118 for Cancer Therapy. USA. 2011 (PCT/ US11/58558).
25. Zander SA, Kersbergen A, van der Burg E, de Water N, van Tellingen O, Gunnarsdottir S, Jaspers JE, Pajic M, Nygren AO, Jonkers J, Borst P and Rottenberg S. Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res 2010; 70: 1700-1710.
26. Ling X, Yang J, Tan D, Ramnath N, Younis T, Bundy BN, Slocum HK, Yang L, Zhou M and Li F. Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in nonsmall-cell lung cancer (NSCLC). Lung Cancer 2005; 49: 353-361.
27. Ling X, Bernacki RJ, Brattain MG and Li F. Induction of survivin expression by taxol (paclitaxel) is an early event which is independent on taxol-mediated G2/M arrest. J Biol Chem 2004; 279: 15196-15203.
28. Shi Z, Tiwari AK, Shukla S, Robey RW, Singh S, Kim IW, Bates SE, Peng X, Abraham I, Ambudkar SV, Talele TT, Fu LW and Chen ZS. Sildenafil reverses ABCB1-and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res 2011; 71: 3029-3041.
29. Chen JJ, Sun YL, Tiwari AK, Xiao ZJ, Sodani K, Yang DH, Vispute SG, Jiang WQ, Chen SD and Chen ZS. PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter. Cancer Sci 2012; 103: 1531-1537.
30. Chen ZS, Lee K and Kruh GD. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 2001; 276: 33747-33754.
31. Jedlitschky G, Burchell B and Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 2000; 275: 30069-30074.
32. Miettinen S, Grenman S and Ylikomi T. Inhibition of P-glycoprotein-mediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposure. Anticancer Drugs 2009; 20: 267-276.
33. Arimori K, Kuroki N, Hidaka M, Iwakiri T, Yamsaki K, Okumura M, Ono H, Takamura N, Kikuchi M and Nakano M. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats. Pharm Res 2003; 20: 910-917.
34. Takeba Y, Sekine S, Kumai T, Matsumoto N, Nakaya S, Tsuzuki Y, Yanagida Y, Nakano H, Asakura T, Ohtsubo T and Kobayashi S. Irinotecan-induced apoptosis is inhibited by in creased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells. Biol Pharm Bull 2007; 30: 1400-1406.
35. Tagen M, Zhuang Y, Zhang F, Harstead KE, Shen J, Schaiquevich P, Fraga CH, Panetta JC, Waters CM and Stewart CF. P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett 2010; 4: 195-201.
36. Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM and Schellens JH. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 2002; 20: 2943-2950.
37. Yamasaki T, Fujinaga M, Kawamura K, Hatori A, Yui J, Nengaki N, Ogawa M, Yoshida Y, Wakizaka H, Yanamoto K, Fukumura T and Zhang MR. Evaluation of the P-glycoproteinand breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography. Nucl Med Biol 2011; 38: 707-714.
38. Gardner ER, Smith NF, Figg WD and Sparreboom A. Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice. J Exp Clin Cancer Res 2009; 28: 99.
39. He Y, Bi Y, Hua Y, Liu D, Wen S, Wang Q, Li M, Zhu J, Lin T, He D, Li X, Wang Z and Wei G. Ultrasound microbubble-mediated delivery of the siRNAs targeting MDR1 reduces drug resistance of yolk sac carcinoma L2 cells. J Exp Clin Cancer Res 2011; 30: 104.
40. Cordo Russo RI, Garcia MG, Alaniz L, Blanco G, Alvarez E and Hajos SE. Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway. Int J Cancer 2008; 122: 1012-1018.
41. Peng H, Qi J, Dong Z and Zhang JT. Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells. PLoS One 2010; 5: e15276.
42. Seo SB, Hur JG, Kim MJ, Lee JW, Kim HB, Bae JH, Kim DW, Kang CD and Kim SH. TRAIL sensitize MDR cells to MDR-related drugs by downregulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3beta pathway and activation of caspases. Mol Cancer 2010; 9: 199.
43. Paillas S, Causse A, Marzi L, de Medina P, Poirot M, Denis V, Vezzio-Vie N, Espert L, Arzouk H, Coquelle A, Martineau P, Del Rio M, Pattingre S and Gongora C. MAPK14/p38alpha confers irinotecan resistance to TP53-defective cells by inducing survival autophagy. Autophagy 2012; 8: 1098-1112.
44. Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13: 714-726.
45. Kawano M, Mabuchi S, Kishimoto T, Hisamatsu T, Matsumoto Y, Sasano T, Takahashi R, Sawada K, Takahashi K, Takahashi T, Hamasaki T and Kimura T. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells. Int J Gynecol Cancer 2014; 24: 829-837.
46. Spigel DR, Waterhouse DM, Lane S, Legenne P and Bhatt K. Efficacy and safety of oral topotecan and bevacizumab combination as secondline treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study. Clin Lung Cancer 2013; 14: 356-363.
47. Trafalis DT, Alifieris C, Krikelis D, Tzogkas N, Stathopoulos GP, Athanassiou AE and Sitaras NM. Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma. Int J Clin Pharm Ther 2012; 50: 490-499.
48. Zarogoulidis K, Mylonaki E, Kakavelas P, Zarogoulidis P, Tsiouda T, Rapti E, Lithoxopoulou H, Zarogoulidou V and Kontakiotis T. Topotecancarboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer. Lung Cancer 2009; 66: 226-230.
49. Choi HJ, Cho BC, Shin SJ, Cheon SH, Jung JY, Chang J, Kim SK, Sohn JH and Kim JH. Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. Cancer Chemother Pharmacol 2008; 61: 309-313.
50. Brave M, Dagher R, Farrell A, Abraham S, Ramchandani R, Gobburu J, Booth B, Jiang X, Sridhara R, Justice R and Pazdur R. Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer. Oncology 2006; 20: 1401-1404, 1410; discussion 1410-1411, 1415-1406.
51. Ardizzoni A, Manegold C, Debruyne C, Gaafar R, Buchholz E, Smit EF, Lianes P, ten Velde G, Bosquee L, Legrand C, Neumaier C and King K. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res 2003; 9: 143-150.
52. Simpson AB, Calvert PM, Sludden JA, Boddy AV, Griffin MJ, Schatzlein A, Wilson P, Fishwick K, Wheatley A, Ross GA, Calvert AH and Twelves CJ. Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules. Ann Oncol 2002; 13: 399-402.
53. Thompson J, George EO, Poquette CA, Cheshire PJ, Richmond LB, de Graaf SS, Ma M, Stewart CF and Houghton PJ. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res 1999; 5: 3617-3631.
54. Gholam D, Giacchetti S, Brezault-Bonnet C, Bouchahda M, Hauteville D, Adam R, Ducot B, Ghemard O, Kustlinger F, Jasmin C and Levi F. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan-and oxaliplatin-resistant metastatic colorectal cancer. Oncologist 2006; 11: 1072-1080.